

Abstract

The invention relates to the use of imidazo[1,5-a]pyrido[3,2-e]pyrazinones of the formula 1 as inhibitors of phosphodiesterase 5 for the therapy of erectile dysfunction (impotence), the use of imidazo[1,5-a]pyrido[3,2-e]pyrazinones of the formula 1 as dual inhibitors of phosphodiesterase 3 and phosphodiesterase 5 for the therapy of heart failure, of pulmonary hypertension and vessel disorders associated with hypoperfusion and process for their preparation.